Coronavirus (COVID-19) Collection
Evaluation of the efficacy of anticoagulation therapy in reducing mortality in a nationwide cohort of hospitalized patients with coronavirus disease in Japan
Globally, coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has affected more than 120 million individuals and caused 2.7 million deaths (Roser et al., 2021). As of 23 March 2021, there have been 457,754 cases and 8861 deaths in Japan (Ministry of Health, Labour and Welfare, 2021), which is lower than the number of cases and deaths reported in other countries with outbreaks of COVID-19 (Roser et al., 2021).Clinical course of alopecia after COVID-19
A 49-year-old man was admitted to our hospital in late March 2020, 6 days after onset of coronavirus disease 2019 (COVID-19). He received remdesivir in a clinical study. Oxygen supplementation was not required. Defervescence occurred 12 days after onset, and he was discharged 21 days after symptom onset. In mid-May 2020, he noticed alopecia on his head. He started taking self-imported minoxidil 5 mg/day and finasteride 1 mg/day in June 2020, and was still taking these medications at the time of writing.
